Table 1.

Demographics and patient disposition by treatment groups.

Demographic variables	10 mg Reg 1, N = 3	20 mg Reg 1, N = 4	40 mg Reg 1, N = 4	80 mg Reg 1, N = 4	150 mg Reg 1, N = 4	300 mg Reg 1, N = 7	400 mg Reg 1, N = 5	300 mg Reg 3, N = 8	500 mg Reg 3, N = 6	700 mg Reg 3, N = 6	All patients, N = 51
Age (years)
Mean (SD)	47 (8.89)	50 (9.13)	50.8 (13.65)	59.3 (5.38)	44.5 (7.0)	58.7 (7.67)	56.8 (12.05)	50.3 (12.51)	56.3 (11.55)	56.7 (8.26)	53.6 (10.33)
Age group (years), n (%)
<65	3 (100)	4 (100)	3 (75.0)	3 (75.0)	4 (100)	5 (71.4)	3 (60.0)	7 (87.5)	5 (83.3)	5 (83.3)	42 (82.4)
≥65	0	0	1 (25.0)	1 (25.0)	0	2 (28.6)	2 (40.0)	1 (12.5)	1 (16.7)	1 (16.7)	9 (17.6)
Sex, n (%)
Male	1 (33.3)	3 (75.0)	3 (75.0)	2 (50.0)	1 (25.0)	2 (28.6)	2 (40.0)	3 (37.5)	2 (33.3)	3 (50.0)	22 (43.1)
Female	2 (66.7)	1 (25.0)	1 (25.0)	2 (50.0)	3 (75.0)	5 (71.4)	3 (60.0)	5 (62.5)	4 (66.7)	3 (50.0)	29 (56.9)
WHO PS, n (%)
0	2 (66.7)	3 (75.0)	3 (75.0)	2 (50.0)	2 (50.0)	4 (57.1)	4 (80.0)	4 (50.0)	3 (50.0)	4 (66.7)	31 (60.8)
1	0	1 (25.0)	0	1 (25.0)	2 (50.0)	2 (28.6)	1 (20.0)	4 (50.0)	3 (50.0)	2 (33.3)	16 (31.4)
2	1 (33.3)	0	1 (25.0)	1 (25.0)	0	1 (14.3)	0	0	0	0	4 (7.8)
Patient disposition, n (%)
Treatment discontinued	3 (100)	4 (100)	4 (100)	4 (100)	4 (100)	6 (85.7)	4 (80.0)	8 (100)	6 (100)	6 (100)	49 (96.1)
Treatment ongoing	0	0	0	0	0	1 (14.3)	1 (20.0)	0	0	0	2 (3.9)
Primary reason for treatment end, n (%)
Adverse event	0	0	0	0	0	1 (14.3)	2 (40.0)	1 (12.5)	0	1 (16.7)	5 (9.8)
Consent withdrawn	0	0	0	0	0	0	0	0	0	1 (16.7)	1 (2.0)
Death	1 (33.3)	0	1 (25.0)	0	0	0	0	0	0	0	2 (3.9)
Disease progression	2 (66.7)	4 (100)	3 (75.0)	4 (100)	4 (100)	5 (71.4)	2 (40.0)	7 (87.5)	6 (100)	4 (66.7)	41 (80.4)

Reg regimen, PS performance status.

Reg 1: 3qw dosing, 4-week treatment cycle, continuous; Reg 3: 3qw dosing, 3-week treatment cycle; 2 weeks on treatment and 1 week off treatment.